Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Immunotherapy Inches Forward in Development of Myeloid Malignancies
Amer Zeidan, MD, MHS, discusses how survival for patients with acute myeloid leukemia and myelodysplastic syndrome remains poor, and although immunotherapy has been positioned as a holy grail, it would be preemptive to predict its future based on the number of small studies that have been performed to date.
Stadtmauer Spotlights the Explosion of BCMA-Directed Therapies in Multiple Myelo...
Edward A. Stadtmauer, MD, highlights the emergence of several BCMA-directed therapies, such as monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies, and how outcomes for patients with multiple myeloma have improved significantly.
Use of daratumumab for transplant-ineligible myeloma
During a Targeted Oncology Case-Based Peer Perspective event, Rafael Fonseca, MD, discussed the case of a 72-year-old patient with multiple myeloma.
Iodine apamistamab conditioning led to 100% bone marrow transplant rate and engr...
Treatment with iodine (131I) apamistamab (Iomab-B) conditioning led to a 100% bone marrow transplant rate and engraftment in patients with active relapsed/refractory acute myeloid leukemia who are older than 55 years old, according to results of a single ad hoc interim analysis of the phase 3 SIERRA study.
Addition of daratumumab further improves the outcomes for patients with relapsed...
Positive trial results for the anti-CD38 mAb, isatuximab, plus pomalidomide and dexamethasone has led to European approval of this combination, but the regimen requires intravenous administration.
Latest updates in myeloma: key takeaways from ASH 2020
Daniel AuClair, PhD, Multiple Myeloma Research Foundation, Norwalk, CT, discusses recent advances in multiple myeloma research that were presented at ASH 2020.